Purpose: Although androgen deprivation therapy (ADT) and androgen receptor (AR)
signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most …

e16539 Background: Abiraterone (A) and enzalutamide (E) are life-prolonging treatments for
metastatic CRPC, yet their potent activity against the androgen receptor (AR) axis often …

Our understanding of-as well as our approach to-castration resistant prostate cancer is
currently undergoing major changes. New drugs like the CYP-17 inhibitor abiraterone have …

After initial response to androgen receptor (AR) targeting drugs abiraterone or
enzalutamide, most patients develop progressive disease and therefore, castration resistant …

Purpose: Despite successful clinical management of castration-sensitive prostate cancer
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer is only …

Prostate cancer is a major health issue in western countries and is the second leading
cause of cancer death in American men. Prostate cancer depends on the androgen receptor …

Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in
combination with enzalutamide in patients with metastatic castration-resistant prostate …

Background The intractability of castration-resistant prostate cancer (CRPC) is exacerbated
by tumour heterogeneity, including diverse alterations to the androgen receptor (AR) axis …

4660 Background: Treatments for CRPC are limited. CRPCs have activation of the PTEN-
PI3K-AKT pathway increasing mTOR expression which drives cell proliferation. We …

Most prostate cancer cases ultimately relapse after a period of initial response to castration
therapy and progress to intractable castration-resistant prostate cancer (CRPC). Hardly any …